Results to your Biomarker

In the field of human biomonitoring (HBM), we offer a comprehensive range of LC-MS and GC-MS-based methods tailored for the precise quantitative determination of environmental chemicals and their specific metabolites in various biological matrices, including urine, serum, plasma and saliva. Our commitment to accuracy and precision is what sets us apart. Our methods are routinely used in biomonitoring campaigns, allowing us to comprehensively assess both occupational and non-occupational exposures to environmental chemicals. At the heart of our services is a commitment to improving understanding of how these substances interact with the human body, ultimately promoting a healthier and more sustainable future.

With over four decades of experience, ABF is a globally leading expert in bioanalysis for biomarkers of exposure related to tobacco and new emerging nicotine products, trusted by clients worldwide. We have analyzed biological samples for hundreds of (non-)clinical studies, applying the largest set of fully validated bioanalytical methods in the field of tobacco harm reduction. We continuously expand our portfolio by developing and validating bioanalytical methods for new biomarkers of exposure and biomarkers of potential harm, staying at the forefront of scientific advancements. At ABF, we are committed to help our clients responsibly launch new nicotine products in the marketplace. Choose ABF for reliable and cutting-edge bioanalysis services in the field of tobacco harm reduction.